More About Our Semaglutide Program:
Is it approved by the FDA?
In June of 2021, the FDA approved specific branded formulations that contain Semaglutide for the chronic treatment of obesity. Traditionally, formulations such as Wegovy and Ozempic containing Semaglutide have been prescribed to treat Type 2 diabetics.
Possible Side Effects:
These side effects are controlled by starting at a low dose and increasing gradually over 16 weeks. Other
medications may stay in your stomach longer and their affect could be
Clients with Type 1 Diabetes, pregnant or nursing or have/had thyroid cancer are NOT candidates for Semaglutide.